Nasdaq · Healthcare
Xeris Biopharma Holdings, Inc. (XERS)
As-reported financials and recent SEC filings for Xeris Biopharma Holdings, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$291.8M
Net income
$554,000
Net margin
0.2%
Diluted EPS
$0.00
ROE
4.0%
P/E (TTM)
109.9×
Market cap
$1.33B
Debt / equity
16.1×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $291.8M | $203.1M | $163.9M | $110.2M | $49.6M |
| Gross profit | — | — | — | — | — |
| Operating income | $24.9M | $-33.6M | $-44.0M | $-81.9M | $-115.2M |
| Net income | $554,000 | $-54.8M | $-62.3M | $-94.7M | $-122.7M |
| Diluted EPS | $0.00 | $-0.37 | $-0.45 | $-0.70 | $-1.55 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
8-K2026-06-11
View on EDGAR →42026-06-05
View on EDGAR →42026-06-05
View on EDGAR →42026-06-05
View on EDGAR →8-K2026-06-05
View on EDGAR →42026-06-05
View on EDGAR →42026-06-05
View on EDGAR →42026-06-05
View on EDGAR →Go deeper on XERS
Search Xeris Biopharma Holdings, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.